Application of euphorbia factor L2 to preparation of medicine for treating acute lung injury
A technology for acute lung injury and euphorbia factor, which is applied in drug combination, antipyretics, and pharmaceutical formulations, and can solve problems such as the absence of euphorbia factor L2
- Summary
 - Abstract
 - Description
 - Claims
 - Application Information
 
 AI Technical Summary 
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0023] Example 1: Pharmacodynamic study of euphorbia factor L2 in the treatment of acute lung injury
[0024] 1. Experimental method
[0025] Thirty-six 8-week-old male C57BL / 6N mice were randomly divided into three groups: the control group, the model group, and the Euphorbia factor L2 treatment group (intraperitoneal injection, 40 mg / kg, administered 2 hours before modeling). They were anesthetized with ketamine (125 mg / kg) and xylazine (8 mg / kg), and 40 μl of sterile PBS or LPS (1 mg / ml, E.coli0111:B4, sigma) were instilled into the trachea, respectively, and the incision was then sutured. The survival rate of mice within 24 h was recorded. After 24 hours, the mice were sacrificed to obtain the lungs, which were fixed and embedded in 4% formaldehyde. The lung tissue was sectioned after dewaxing and dehydration, and hematoxylin-eosin (Hematoxylin-Eosin, HE) was used for pathological analysis. After 24 hours, bronchial alveolar lavage fluid (BALF) was collected and centrif...
PUM
 Login to View More Abstract
Description
Claims
Application Information
 Login to View More - R&D
 - Intellectual Property
 - Life Sciences
 - Materials
 - Tech Scout
 
- Unparalleled Data Quality
 - Higher Quality Content
 - 60% Fewer Hallucinations
 
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com



